“CID-078 exemplifies Circle Pharma’s commitment to advancing new treatments for patients with cancer,” said Michael C. Cox, PharmD, MHSc, BCOP, SVP, and head of early development of Circle Pharma.

The two articles describe the physical interactions between the retinoblastoma protein and D cyclins, a basic discovery in cell biology that has ramifications for the study of cancer. Both types of ...